AbCellera is at the forefront of developing innovative antibody medicines, focusing on creating potential first-in-class and best-in-class therapies. The company has established advanced technology platforms that facilitate the discovery and development of high-value drug classes and targets, particularly in the areas of transmembrane proteins, T-cell engagers, and peptide-MHC complexes. Their T-cell engager platform is particularly noteworthy, as it utilizes a diverse array of CD3-binding antibodies to generate bispecific antibodies that can effectively kill tumor cells while minimizing cytokine release, thereby addressing significant safety concerns associated with cancer therapies. Additionally, AbCellera's technology enables the identification of antibodies that are highly specific to MHC-peptide complexes, broadening the range of targets available for T-cell engagers in solid tumors.

To streamline the transition from target identification to clinical application, AbCellera has developed an integrated engine that combines expert teams, cutting-edge technology, and data science. This engine supports optimized workflows necessary for advancing therapeutic programs from concept to clinical trials. Their discovery process includes immunization of various species, high-throughput single-cell screening, and detailed characterization of lead candidates. Furthermore, AbCellera is in the process of establishing a clinical manufacturing facility to produce GMP drug substances, which will enhance their capability to scale up production and facilitate the transition of promising candidates into clinical development.

Canada

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

Cancer

Cardiovascular Diseases

Infectious Diseases

Nervous System Diseases

AbCellera

COVID-19

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the &nbsp;&nbsp;&nbsp;&nbsp;prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months &nbsp;&nbsp;&nbsp;&nbsp;after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken &nbsp;&nbsp;&nbsp;&nbsp;from one of the first U.S. patients who recovered from COVID-19.
Source

Bamlanivimab (LY-CoV555)

Preclinical data show LY-CoV1404 potently neutralizes SARS-CoV-2 and all current variants identified and reported to be of concern in this pandemic. LY-CoV1404 blocks viral binding to ACE2 by targeting a highly conserved epitope on the SARS-CoV-2 spike glycoprotein receptor binding domain (RBD), providing a strong, well-documented mechanism for the potent neutralizing activity.
 
LY-CoV1404 uniquely binds a conserved region of the SARS-CoV-2 RBD that is distinct from other neutralizing antibodies. While the LY-CoV1404 binding epitope includes amino acid residues N501 and N439, LY-CoV1404 neutralizes B.1.1.7 and B.1.351, which both carry the N501Y mutation, as potently as wild type virus in pseudovirus assays and retains full functional neutralization against pseudovirus with the N439K mutant.

AbCellera

Company Details